| Literature DB >> 29152433 |
Saeed K Alzghari1, Victor Fung2, Shannon S Rickner3, Liza Chacko4, Steven W Fleming4.
Abstract
Cannabis use is steadily rising in the United States. As the popularity of marijuana rises, new varieties of cannabis-related products are becoming available. Dabs are cannabis concentrates gaining notoriety for their significant amounts of tetrahydrocannabinol (THC) that are ultimately vaporized and inhaled for their effect. Herein, we provide an overview of recent cases of dabbing to bring awareness to the clinicians, of the significant adverse effects associated with dabs including psychosis, neurotoxicity, and cardiotoxicity.Entities:
Keywords: cannabis; cannabis concentrates; cardiotoxicity; dabbing; dabs; marijuana; neurotoxicity; psychosis
Year: 2017 PMID: 29152433 PMCID: PMC5679763 DOI: 10.7759/cureus.1676
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Structures of cannabidiol and delta-nine-tetrahydrocannabinol (THC).
Recent case reports involving the use of “dabs” and their outcomes.
Abbreviations: h: hour, HD: hospital day, kg: kilograms, LCMS: liquid chromatography-mass spectrometry, mcg: micrograms, mg: milligrams, mmHg: millimeters of mercury, ng/mL: nanograms per milliliter, THC: tetrahydrocannabinol, TID: three times per day.
| Author | Date | Country | Age (Years) | Sex | Drug(s) | Route | Urine THC Level | Presentation | Treatment and Outcome |
|
Rickne, et al. [ | June 2017 | USA | 17 | M | Dabs; e-cigarette | Inhalation | carboxy-THC: 108 ng/mL (detection limit 15 ng/mL) | Seizure-like activity; alert but agitated; hyperthermic; hypertensive with systolic blood pressures in the 190s; twitches and jerks of his extremities; elevated troponins; liquid chromatography-mass spectrometry (LCMS) of dab sample contained THC at 20.5% and cannabidiol (CBD) was undetectable | Received propofol infusion (75 mcg/kg/min) followed by midazolam (2.5 mg/h) and fentanyl (125 mcg/h) for sedation; patient discharged without neurologic sequelae after five-day hospital stay |
|
Pierre, et al. [ | Feb 2016 | USA | 17 | M | Recreational cannabis; cannabis wax | Inhalation | N/A | Over the course of three weeks after using cannabis wax, experienced paranoia; appeared confused, disorganized, and agitated; mild fever; tachycardia (up to 110 beats/minute); hypertension (up to 170/90 mmHg); diaphoresis; photophobia | Received risperidone 3 mg/day over one week where he returned to baseline mental status after 12-day hospital stay |
|
Pierre, et al. [ | Feb 2016 | USA | 26 | M | Medical marijuana; cannabis wax (“Fire OG” and “Mystery”) | Inhalation | N/A | Over the course of 18 months, the patient became increasingly restless, confused, and disorganized; signs of paranoia | Treated with olanzapine 20 mg/day on HD one, transitioned to risperidone 2 mg/day on HD two, risperidone discontinued on HD three with little improvement; by HD seven and eight, patient experienced catatonia resulting in initiation of lorazepam 2 mg three times per day(TID) that resulted in resolution of catatonia followed by restarting risperidone 4 mg/day; discharged after 17-day hospital stay |